Long-Term Prognostic Significance of Neoangiogenesis in Breast Carcinomas: Comparison of Tie-2/Tek, CD105, and CD31 Immunocytochemical Expression

Human Pathology

Volumn 35, Issue 2, 2004, Pages 176-183

  Dales, Jean P ^b   Garcia, Stephane ^b   Carpentier, Severine ^b   Andrac, Lucile ^b   Ramuz, Oliver ^b   Lavaut, Marie N ^b   Allasia, Claude ^b   Bonnier, Pascal ^b   Charpin, Colette ^a  

^a HÔPITAL NORD   (France)

^b NONE

Author keywords

Breast cancer; CD105; CD31; Immunohistochemistry; Prognosis; Tie 2 Tek

Indexed keywords

ANGIOPOIETIN RECEPTOR; CD105 IMMUNOTOXIN; CD31 ANTIGEN; ENDOGLIN; IMMUNOTOXIN; T LYMPHOCYTE ANTIGEN; UNCLASSIFIED DRUG;

ADULT; AGED; ANGIOGENESIS; ARTICLE; BIOLOGICAL MONITORING; BREAST CANCER; CANCER PATIENT; CANCER SURGERY; CANCER SURVIVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG TARGETING; HUMAN; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; KAPLAN MEIER METHOD; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MASTECTOMY; MULTIMODALITY CANCER THERAPY; PATIENT MONITORING; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN TARGETING; TREATMENT OUTCOME;

EID: 1242274547     PISSN: 00468177     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.humpath.2003.10.008     Document Type: Article

References (36)

1. McGuire WL, Clark GM: Prognostic factors and treatment decisions in axillary node-negative breast cancer. N Engl J Med 326:1756-1760, 1992
2. Ellis LM, Fidler IJ: Angiogenesis and breast cancer metastasis. Lancet 346:388-389, 1995
3. Gasparini G: Clinical significance of the determination of angiogenesis in human breast cancer: Update of the biological background and overview of the Vicenza studies. Eur J Cancer 32A:2485-2493, 1996
4. Fox SB, Gasparini G, Harris AL: Angiogenesis: Pathological, prognostic and growth-factor pathways and their link to trial design and anticancer drugs. Lancet Oncol 2:278-289, 2001
5. Gasparini G: Angiogenesis research up to 1996: A commentary on the state of art and suggestions for future studies. Eur J Cancer 14:2379-2385, 1996
6. Charpin C, Devictor B, Bergeret D, et al: CD31 quantitative immunocytochemical assays in breast carcinomas: Correlation with current prognostic factors. Am J Clin Pathol 103:443-448, 1995
7. Charpin C, Garcia S, Bouvier C, et al: CD31/PECAM automated and quantitative immunocytochemical assays in breast carcinomas: Correlations with patient follow-up. Am J Clin Pathol 107:534-541, 1997
8. Kumar S, Ghellal A, Li C, et al: Breast carcinoma: Vascular density determined using CD105 antibody correlates with tumor prognosis. Cancer Res 59:856-861, 1999
9. Peters KG, Coogan A, Berry D, et al: Expression of Tie2/Tek in breast tumor vasculature provides a new marker for evaluation of tumor angiogenesis. Br J Cancer 77:51-56, 1998
10. Tanaka F, Otake Y, Yanagiharaa K, et al: Evaluation of angiogenesis in non-small cell lung cancer: Comparison between anti-CD34 antibody and anti-CD105 antibody. Clin Cancer Res 7:3410-3415, 2001
11. Seon BK, Matsuno F, Haruta Y, et al: Long-lasting complete inhibition of human solid tumors in SCID mice by targeting endothelial cells of tumor vasculature with antihuman endoglin immunotoxin. Clin Cancer Res 3:1031-1044, 1997
12. Matsuno F, Haruta Y, Kondo M, et al: Induction of lasting complete regression of preformed distinct solid tumors by targeting the tumor vasculature using two new anti-endoglin monoclonal antibodies. Clin Cancer Res 5:371-382, 1999
13. Fonsatti E, Del Vecchio L, Altomonte M, et al: Endoglin: An accessory component of the TGF-beta-binding receptor-complex with diagnostic, prognostic and bioimmunotherapeutic potential in human malignancies. J Cell Physiol 188:1-7, 2001
14. Hanahan D: Signaling vascular morphogenesis and maintenance. Science 277:48-50, 1997
15. Hatva E, Kaipainen A, Mentula P, et al: Expression of endothelial cell-specific receptor tyrosine kinases and growth factors in human brain tumors. Am J Pathol 146:368-378, 1995
16. Kaipainen A, Vlaykova T, Hatva E, et al: Enhanced expression of the Tie receptor tyrosine kinase mesenger RNA in the vascular endothelium of metastatic melanomas. Cancer Res 54:6571-6577, 1994
17. Salven P, Joensuu H, Heikkila P, et al: Endothelial Tie growth factor receptor provides an antigenic marker for assessment of breast cancer angiogenesis. Br J Cancer 74:69-72, 1996
18. Bloom HG, Richardson WW: Histological grading and prognosis in breast cancer. Br J Cancer 11:359-377, 1957
19. Elston CN, Ellis IO: Pathological prognostic factors in breast cancer, I. The value of the histological grade in breast cancer: Experience from a large study with long-term follow-up. Histopathology 19:403-410, 1991
20. Charpin C, Martin PM, Devictor B, et al: Multiparametric study (SAMBA 200) of estrogen receptor immunocytochemical assay in 400 human breast carcinomas, analysis of estrogen receptor distribution heterogeneity in tissues, and correlations with dextran-coated charcoal assays and morphological data. Cancer Res 48:1578-1586, 1988
21. Charpin C, Jacquemier J, Andrac L, et al: Multiparametric analysis (SAMBA 200) of the progesterone receptor immunocytochemical assay in non-malignant and malignant breast disorders. Am J Pathol 132:199-211, 1988
22. Lastres P, Bellon T, Cabanas C, et al: Regulated expression on human macrophages of endoglin, an Arg-Gly-Asp-containing surface antigen. Eur J Immunol 22:393-397, 1992
23. Folkman J: Clinical applications of research on angiogenesis. N Engl J Med 333:1757-1763, 1995
24. Vermeulen PB, Gasparini G, Fox SB, et al: Quantification of angiogenesis in solid human tumors: An international consensus on the methodology and criteria of evaluation. Eur J Cancer 32A:2474-2484, 1996
25. Goulding H, Nik Abdul Rashid NF, Robertson JF, et al: Assessment of angiogenesis in breast carcinoma: An important factor in prognosis? Hum Pathol 26:1196-1200, 1995
26. Costello P, McCann A, Carney DN, et al: Prognostic significance of microvessel density in lymph node-negative breast carcinoma. Hum Pathol 26:1181-1184, 1995
27. Weidner N, Folkman J, Pozza F, et al: Tumor angiogenesis: A new significant and independent prognostic indicator in early-stage breast carcinoma. J Natl Cancer Inst 84:1875-1887, 1992
28. Altman DG, Lausen B, Sauerbrei W, et al: Dangers of using "optimal" cutpoints in the evaluation of prognostic factors. J Natl Cancer Inst 86:829-835, 1994
29. Wang JM, Kumar S, Pye D, et al: A monclonal antibody detects heterogeneity in vascular endothelium of tumors and normal tissues. Int J Cancer 54:363-370, 1993
30. Stratmann A, Risau W, Plate KH: Cell type-specific expression of angiopoietin-1 and angiopoietin-2 suggests a role in glioblastoma angiogenesis. Am J Pathol 153:1459-1466, 1998
31. Holash J, Maisonpierre PC, Compton D, et al: Vessel cooption, regression and growth in tumors mediated by angiopoietins and VEGF. Science 284:1994-1998, 1999
32. Tanaka S, Sugimachi K, Yamashita Y, et al: Tie2 vascular endothelial receptor expression and function in hepatocellular carcinoma. Hepatology 35:861-867, 2002
33. Lin P, Buxton JA, Acheson A, et al: Antiangiogenic gene therapy targeting the endothelium-specific receptor tyrosine kinase Tie2. Proc Natl Acad Sci U S A 95:8829-8834, 1998
34. Siemeister G, Schirner M, Weindel K, et al: Two independent mechanisms essential for tumor angiogenesis: Inhibition of human melanoma xenograft growth by interfering with either the vascular endothelial growth factor receptor pathway or the Tie-2 pathway. Cancer Res 59:3185-3191, 1999
35. Lin P, Polverini P, Dewhirst M, et al: Inhibition of tumor angiogenesis using a soluble receptor establishes a role for Tie2 in pathologic growth. J Clin Invest 100:2072-2078, 1997
36. Korhonen J, Polvi A, Partanen J, et al: The mouse tie receptor tyrosine kinase gene: Expression during embryonic angiogenesis. Oncogene 9:395-403, 1994